Aleksandar Danilovski Email Address

Managing Director

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against

Xellia Pharmaceuticals is a global specialty pharmaceutical company focused on providing clinically effective hospital care injectable products against serious and often life-threatening diseases. Mid 2013, Xellia was acquired by The Novo Nordisk Foundation with the intent of supporting the company's vision of establishing itself as a leader in the anti-infective hospital care market. Proudly leveraging over 100 years of our Scandinavian heritage with experience in the pharmaceutical business, and additionally fueled with the new long term ownership, we are more than ever committed to further expand our portfolio of differentiated products with increased patient compliance and improved efficacy and to continuously enhance and grow our successful business.